Resources

Co-designing new networks with research users is critical to delivering the full scientific and commercial value of NHS health data.

The data the biotech industry generates, consumes and shares is very often not only extremely sensitive (expensive to create, the product of some of the finest minds and technically focused facilities on the earth, in some cases connectable to the very fabric of humanity), it’s impossible to de-sensitise once lost to an attacker. 

OMass Therapeutics Strengthens its Leadership Team with the Promotions of Hsin Loke to Chief Operating officer and Jon Roffey to Senior Vice President, Discovery and Non-Clinical

Imperial, the leading global science university, is achieving a major step up in its life sciences capacity at its White City Deep Tech Campus through a major new joint venture with Bruntwood SciTech.

We are excited to welcome the newly elected members of the BIA Board of Directors, who will bring fresh insights and expertise to help drive our mission forward. Nick Gardiner shares his perspective on the importance of these appointments and the unique value each new Director brings to the BIA.

The UK biotech sector demonstrated encouraging resilience in the third quarter of 2024 raising a total of £808 million in venture capital and public financing. Read our latest report to find out more.

The UK biotech sector secured an impressive £808 million in Q3 2024, defying tough global market conditions and demonstrating sustained investor confidence. Read our latest report to find out more.

The UK is a global leader in TechBio, drawing substantial investments and nurturing a vibrant ecosystem of talent and businesses, reveals a report launched today by the BIA.

In this insightful blog, Louis Taylor, CEO of the British Business Bank, explores how the Mansion House reforms and increased pension fund investments could unlock billions in domestic capital, fueling the next generation of UK innovators.

Symbiosis Pharmaceutical Services Ltd announces the purchase of new premises in Stirling, Scotland, UK. The additional space will double the total footprint of the company across the four facilities that it will operate from, increasing manufacturing capacity by 50% in the short-term.

Steve Bates OBE, CEO of the BIA, responded to the announcement of a new Regulatory Innovation Office.

The BIA’s policy and public affairs team attended the conferences of the three major UK parties this year. This is a key point in the political calendar and allows us to highlight the sector through fringe events, meet policymakers, and get a sense of the political environment.

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, recaps the recent Women in Biotech event in Manchester, where industry leaders discussed talent attraction, female leadership, and career advancement. The panel highlighted the importance of fostering home-grown talent, supporting female role models, and offering mentorship opportunities.

Financing led by Ahren, OMX Ventures and Paladin Capital Group represents one of the largest UK biotech Series A rounds in recent years.

Quell Therapeutics expands manufacturing capabilities for CAR-Treg cell therapy pipeline through partnership with eXmoor pharma. The multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies.

LinkGevity, an AI-driven drug discovery company focused on longevity and age-related disease, announces its selection for the highly competitive SPACE-H Accelerator program, powered by Starburst in collaboration with NASA’s Human Research Program (NASA HRP), the Translational Research Institute for Space Health (TRISH), and Microsoft Federal (Microsoft).